Of note, hematopoietic-restricted expression of Zeb2 does lead to the development of ETP-ALL from 6 months of age onward [15] and only leads to AML development when intercrossed onto a p53 conditional null tumor-prone background [15]. This evidence concerns the gene ZEB2 and acute myeloid leukemia.